A pilot psychedelic psychopharmacology elective

Cusimano, Joseph

doi:10.1016/j.cptl.2022.04.019

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, many of them may work in psychiatric in-patient or collaborative mental health primary care settings and thus are not employed within a traditional community dispensary setting. 3 As an alternative, it is worth considering a number of other psychedelic educational training programs that currently exist or whose content may be adaptable for the role of the pharmacist (Cusimano, 2022; Psychedelic Support, 2022).…”

Section: Introductionmentioning

confidence: 99%

A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness

Brandt

2023

Drug Science, Policy and Law

View full text Add to dashboard Cite

The unprecedented progress in the science and clinical investigation of psychedelic medicine will require those in healthcare leadership and the legislative policy arena to conceptualize how future reforms, policy creation, and clinical practice should occur to broaden access to these agents while simultaneously maximizing effectiveness and mitigating harm. The pharmacy profession has surprisingly had little engagement on this front. This article provides a perspective commentary and overview of potential future strategies in legal reform, professional regulatory authority policy creation, and pharmacy operations regarding the psychedelic agents’ psilocybin and methylenedioxymethamphetamine, using Canada as a national case study.

show abstract

Section: Introductionmentioning

confidence: 99%

A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness

Brandt

2023

Drug Science, Policy and Law

View full text Add to dashboard Cite

show abstract

Ethics of Psychedelic Use in Psychiatry and Beyond—Drawing upon Legal, Social and Clinical Challenges

Azevedo,

Oliveira Da Silva,

Madeira

2023

Philosophies

View full text Add to dashboard Cite

Background: Psychedelics are known for their powerful mental effects due to the activation of 5HT-2A receptors in the brain. During the 1950s and 1960s, research was conducted on these molecules until their criminalization. However, their clinical investigation as therapeutic tools for psychiatric disorders has revived the deontological ethics surrounding this subject. Questions arise as research on their therapeutic outcome becomes a reality. We aim to explore deontological ethics to understand the implications of psychedelics for the clinician, patient, and society. Results: A total of 42 articles were considered for this review. Methods: A methodological search of psychedelic studies from 2017 to 2022 was conducted in PubMed, Scopus, EBSCOhost, and ScienceDirect to address the deontological ethics of clinical psychedelic use. Conclusion: Psychedelics need to be culturally contextualized, epistemic harm minimized and represented to ensure informed consent. Open data and commissions are needed to ensure safe and equal distribution.

show abstract

A pilot psychedelic psychopharmacology elective

Cited by 2 publications

References 16 publications

A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness

A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness

Ethics of Psychedelic Use in Psychiatry and Beyond—Drawing upon Legal, Social and Clinical Challenges

Contact Info

Product

Resources

About